Edition:
United States

Kite Pharma Inc (KITE.OQ)

KITE.OQ on NASDAQ Stock Exchange Global Select Market

73.11USD
26 May 2017
Change (% chg)

$-1.80 (-2.40%)
Prev Close
$74.91
Open
$74.80
Day's High
$76.19
Day's Low
$72.40
Volume
382,701
Avg. Vol
452,666
52-wk High
$88.58
52-wk Low
$39.83

Latest Key Developments (Source: Significant Developments)

Kite receives U.S. FDA priority review for Axicabtagene Ciloleucel
Friday, 26 May 2017 10:47am EDT 

May 26 (Reuters) - Kite Pharma Inc :Kite receives U.S. Food and Drug Administration priority review for Axicabtagene Ciloleucel.Kite Pharma Inc - Prescription Drug User Fee Act (PDUFA) set for November 29, 2017.Kite Pharma Inc - Biologics License Application submission based on primary analysis of ZUMA-1 Phase 2 trial.Kite Pharma Inc - ‍Expects to submit its Market Authorization Application (MAA) of Axicabtagene Ciloleucel with European Medicines Agency in Q3 of 2017​.  Full Article

Kite Pharma says one patient in KTE-C19 study died
Monday, 8 May 2017 09:12am EDT 

May 8 (Reuters) - Kite Pharma Inc :Kite says one patient in safety study testing cancer drug, KTE-C19, developed multiple organ failure and then fatal cerebral edema: conf call.  Full Article

Kite Pharma reports Q1 non-GAAP loss per share of $1.28
Monday, 8 May 2017 08:00am EDT 

May 8 (Reuters) - Kite Pharma Inc :Kite reports first quarter financial results.Q1 non-GAAP loss per share $1.28 excluding items.Q1 loss per share $1.74.Q1 revenue $9.8 million.Q1 revenue view $12.3 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-1.71 -- Thomson Reuters I/B/E/S.Continues to expect full year 2017 net cash burn to be between $325 million and $340 million.  Full Article

Kite Pharma names Richard Wang CEO of Fosun Kite Biotechnology Co Ltd
Sunday, 5 Mar 2017 04:00pm EST 

Kite Pharma Inc : Richard L. Wang named chief executive officer of Fosun Kite Biotechnology Co, Ltd, a joint venture to lead development of axicabtagene ciloleucel and other engineered T-cell therapies for treatment of cancers in China .Richard wang named CEO of Fosun Kite Biotechnology Co Ltd.  Full Article

Kite reports pricing of public offering of common stock
Thursday, 2 Mar 2017 09:23am EST 

Kite Pharma Inc : Kite announces pricing of public offering of common stock .Says public offering of 4.75 million common shares priced at $75.00 per share.  Full Article

Kite Pharma posts Q4 adj. loss per share $1.31
Tuesday, 28 Feb 2017 08:00am EST 

Kite Pharma Inc : Kite reports fourth quarter and full year 2016 financial results . Q4 non-GAAP loss per share $1.31 excluding items . Says expects to have sufficient cash resources to fund its current operations through first half of 2018 . Q4 loss per share $1.70 . Q4 earnings per share view $-1.75 -- Thomson Reuters I/B/E/S . Sees FY 2017 revenue $40 million to $50 million . Q4 revenue $4.9 million versus I/B/E/S view $5.6 million .Sees full year 2017 GAAP operating expenses to be between $490 million and $515 million.  Full Article

Kite Pharma establishes strategic partnership with Daiichi Sankyo
Monday, 9 Jan 2017 04:23pm EST 

Kite Pharma Inc : Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan . Kite Pharma - Daiichi Sankyo will make an upfront payment to kite of $50 million . Kite Pharma says will be eligible to receive future payments totaling up to $200 million for development and commercial milestones . Kite Pharma says is also entitled to receive sales royalties in the low to mid double digit range .Kite pharma - under terms, Daiichi Sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in Japan.  Full Article

Kite Pharma submitted an investigational new drug application with FDA
Tuesday, 3 Jan 2017 08:30am EST 

Kite Pharma Inc :Kite pharma - submitted an investigational new drug (ind) application with U.S. Food and drug administration to initiate a phase 1 trial of kite-718.  Full Article

Kite Pharma Q2 non-gaap loss per share $0.91 excluding items
Monday, 8 Aug 2016 04:05pm EDT 

Kite Pharma Inc : Q2 loss per share $1.31 . Kite pharma reports second quarter 2016 financial results . Q2 non-gaap loss per share $0.91 excluding items . Q2 revenue $4.8 million versus i/b/e/s view $4.9 million .Q2 earnings per share view $-1.21 -- Thomson Reuters I/B/E/S.  Full Article

Biolife Solutions says entered into 10-year supply agreement with Kite Pharma
Monday, 11 Jul 2016 06:30am EDT 

Biolife Solutions Inc : Biolife solutions executes 10 year supply agreement with kite pharma for Cryostor use in CAR T cell therapies . Agreement provides for Kite's supply of Biolife's Cryostor clinical grade freeze media for cells and tissues .Says entered into a ten year supply agreement with Kite Pharma.  Full Article

More From Around the Web

Kite CAR-T gets FDA priority review, Juno shares fall

May 26 Kite Pharma Inc on Friday said the U.S. Food and Drug Administration will review its experimental drug axicabtagene ciloleucel on a priority basis as a treatment for advanced non-Hodgkin lymphoma, a cancer that starts in white blood cells.